# Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

> **NCT01042392** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 506 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Ramipril
- **DRUG:** Matching placebo to Aliskiren
- **DRUG:** Matching placebo to Ramipril

## Key facts

- **NCT ID:** NCT01042392
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2012-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042392, "Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01042392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*